title: Etanercept and uveitis: friends or foes?
authors.affiliation: Laboratory of Autoimmune Diseases Josep Font, Cellex, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune Diseases, Hospital Clínic , Barcelona , Spain.
authors.forename: Pilar
authors.initials: P
authors.lastname: Brito-Zerón
authors.forename: Roberto
authors.initials: R
authors.lastname: Perez-Alvarez
authors.forename: Manuel
authors.initials: M
authors.lastname: Ramos-Casals
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology; D015551:Autoimmunity / Q000187:drug effects*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology; D011358:Product Surveillance, Postmarketing; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014605:Uveitis / Q000188:drug therapy / Q000209:etiology / Q000276:immunology
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept
keywords: Adalimumab; Ankylosing spondylitis; Etanercept; Infliximab; Uveitis